Health
Could Coronavirus Variants Boost Pfizer’s Vaccine Sales By 50%? – Motley Fool
Probably not in the way some might think.
Fifteen billion dollars: That’s how much Pfizer(NYSE:PFE)projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Sure, the company splits profits equally with its partner, BioNTech(NASDAQ:BNTX), but we’re still talking about a lot of money.
The actual amount will almost surely be even higher. Since Pfizer’s update, the U.S. government has ordered another 100 million doses of BNT162b2. But could Pfizer’s revenue from the vaccine be 50% higher because…
-
Business4 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General7 hours agoAlbanese beats drum on economy as trade clouds gather
-
General5 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General5 hours agoHow a fake expert crashed the World | The West Report